Source of this article: Tianfeng Securities "Pharmaceutical and Biological Industry: assisted Reproductive Technology is expected to be included in Medical Insurance, and the prosperity of the industry continues to improve"
Events:
Recently, in response to the proposal, National Healthcare Security Administration proposed that qualified fertility support drugs, such as bromocriptine, triptorelin, clomiphene, and other ovulation-inducing drugs have been included in the scope of health insurance payments, raising the level of drug security for some patients, and will gradually bring appropriate labor analgesia and assisted reproductive technology projects into the scope of payment of the fund, and strive to reduce the medical burden on infertile patients and improve the level of medical security.
Explore the inclusion of assisted reproduction in health insurance and commercial insurance
On August 17, 2022, 17 departments, including the National Health Commission and the National Development and Reform Commission, issued the guidance on further improving and implementing active Fertility support measures. For the first time, it is clearly proposed to guide local governments to gradually bring appropriate labor analgesia and assisted reproductive technology projects into the scope of medical insurance (including maternity insurance) fund payments. In May 2022, Zhejiang Medical Insurance Bureau proposed to bring assisted reproduction-related technology and medical services into the scope of maternity insurance payment. In April 2022, the Jiangsu Provincial Medical Insurance Bureau said it would conduct a special study on the types of payments related to assisted reproductive diagnosis and treatment programs. In February 2022, the Hunan Provincial Medical Insurance Bureau said it would gradually explore the inclusion of medical insurance affordable therapeutic assisted reproductive technology into the scope of health insurance payments. The inclusion of assisted reproductive technology in health insurance is expected to expand the infertility population benefited by the technology and alleviate the financial burden of families.
Fertility subsidies are explored in many places, and fertility support policies have entered the landing stage.
On January 17, 2022, the National Bureau of Statistics announced that the national population at the end of 2022 was 1.41175 billion, 850000 less than that at the end of the previous year, with a natural population growth rate of-0.60 ‰ and 9.56 million births in 2022. In the face of the challenges such as the aging of the population, the increasing proportion of women of childbearing age and the increase of the age of first marriage and childbearing, the demand for assisted reproduction may further increase in the future, and more places to explore fertility subsidies. In January 2023, the Shenzhen Health Commission openly solicited the opinions of the "Shenzhen Municipal measures for the Administration of Child Care subsidies" and proposed to issue child care subsidies, totaling 19000 yuan in three years for giving birth to a third child. Jinan City, Shandong Province plans to grant a monthly child-rearing subsidy of 600 yuan per child to families born after January 1, 2003 to the age of 3.
The prosperity of the assisted reproductive industry has improved
The report of the 20th CPC National Congress proposed to optimize the population development strategy and establish a policy system for fertility support. At the symposium on population work held by the National Health Commission in October 2022, it was pointed out that it is necessary to speed up the establishment of a policy system for fertility support. Assisted reproduction is an important technical means of fertility security, which is of great significance to promote the long-term and balanced development of population. Under the background of the change of population structure, the increase of infertility and the increase of penetration rate of assisted reproductive technology, the increasing improvement of the policy support system is expected to further improve the prosperity of the assisted reproductive industry.
Give full play to the advantages of traditional Chinese medicine in the treatment of infertility and increase the construction of talent echelon
The State Health Commission and the State Administration of traditional Chinese Medicine have called for further strengthening the work of traditional Chinese medicine in the field of women and children to provide quality Chinese medicine services for couples who need to give birth. At present, the State Administration of traditional Chinese Medicine is working out a plan for the implementation of a special action on health promotion of traditional Chinese medicine, encouraging traditional Chinese medicine hospitals to set up eugenics clinics and provide diagnosis and treatment services for infertility. Western medicine gynaecologists and obstetrics clinicians are encouraged to study traditional Chinese medicine, and gynaecologists with senior titles in traditional Chinese medicine institutions are encouraged to practice in multiple places.
Related enterprises:
Recommended attention: ① assisted reproductive medical institutions:$Jinxin Fertility (01951.HK)$、$Xi'An International Medical Investment (000516.SZ)$② TCM diagnosis and treatment Institution:$GUSHENGTANG (02273.HK)$③ upstream reagent enterprises: recommended attention$BASECARE-B (02170.HK)$等
Risk hints: market shock risk, performance lower than expected, individual company extension integration less than expected, epidemic risk
Edit / Somer